According to a large scale screening of 10,587 biopsy samples from 7,121 patients with NSCLC, 6% of patients harbored MDM2 amplification, with an enrichment in patients concurrently carrying EGFR mutation (8%) and ALK translocation (10%) [15]. Here, MDM2 is linked to non-small cell lung carcinoma.